You have read all your free articles, to continue reading subscribe to read the rest of this content.
BioArctic has announced that data from the ongoing BAN2401 Phase 2b open-label extension study in early Alzheimer’s disease patients was presented by Eisai at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Diego, US. A subset of patients from the core Phase 2b study enrolAlready a subscriber Login…
Gesynta Pharma reports positive Phase I results with its lead candidate GS-248 for microvascular disease. Results from the completed First-in-Human clinical study with GS-248 for the treatment of microvascular disease have been presented at the EULAR 2020 E-Congress. Following these results, GAlready a subscriber Login You have read all your…
Biovica has been selected by the European Commission to receive support for a project as part of the Horizon 2020 phase 2 program. Biovica’s project “Clinical validation of the DiviTum assay in two high profile clinical studies in Europe” is receiving € 682,000 and being undertaken with a EuAlready a…
Gedea Biotech has announced that results from a recently published study show that their pHyph antibiotic-free treatment for bacterial vaginosis has a high cure rate and prevents recurrence of the infection. Titled “A novel non-antimicrobial treatment of bacterial vaginosis: An open label two-pAlready a subscriber Login You have read all…
